Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR.
BACKGROUND
Recent studies have shown that the phosphatidylinositol 3-kinase (PI3K) signaling pathway is important regulator of many cellular events, including apoptosis, proliferation and motility. PI3K pathway alterations (PIK3CA gene mutations and/or amplification) have been observed in various human tumours. In the majority of diagnosed cases, mutations are localized in one of the three "hot spots" in the gene, responsible for coding catalytic subunit α of class I PI3K (PIK3CA). Mutations and amplification of PIK3CA gene are characteristic for thyroid cancer, as well.


METHODS
The aim of our study was to examine a gene expression level of PIK3CA in fine-needle aspiration biopsy (FNAB) thyroid specimens in two types of thyroid lesions, papillary thyroid carcinoma (PTC) and non-toxic goitre (NTG). Following conventional cytological examination, 42 thyroid FNAB specimens, received from patients with PTC (n = 20) and NTG (n = 22), were quantitatively evaluated regarding PIK3CA expression level by real-time PCR in the ABI PRISM® 7500 Sequence Detection System.


RESULTS
Significantly higher expression level (RQ) of PIK3CA in PTC group has been noted in comparison with NTG group (p < 0.05).


CONCLUSIONS
These observations may suggest role of PIK3CA alterations in PTC carcinogenesis.
Wojciechowska-Durczyńska
Katarzyna
K
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland. kacha80@poczta.fm.
Krawczyk-Rusiecka
Kinga
K
Cyniak-Magierska
Anna
A
Zygmunt
Arkadiusz
A
Gałecka
Elzbieta
E
Lewiński
Andrzej
A
Nat Genet. 1999 Jan;21(1):99-102
9916799
Cell Cycle. 2004 Oct;3(10):1221-4
15467468
J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93
15928251
Cancer Biol Ther. 2004 Aug;3(8):772-5
15254419
Cancer Res. 2005 Nov 15;65(22):10199-207
16288007
Br J Cancer. 2006 Feb 27;94(4):455-9
16449998
Curr Opin Oncol. 2006 Jan;18(1):77-82
16357568
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
18000091
Endocr J. 2003 Feb;50(1):77-83
12733712
J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90
17426084
Trends Biochem Sci. 2007 Oct;32(10):450-6
17920279
Clin Cancer Res. 2007 Feb 15;13(4):1161-70
17317825
Trends Biochem Sci. 2007 Jul;32(7):342-9
17561399
Thyroid. 2010 Jul;20(7):697-706
20578891
Oncogene. 2000 May 25;19(23):2739-44
10851074